(Q52001329)

19 April 2018

title

The role of general practitioners in the diagnosis and treatment of Alzheimer's disease: a multinational survey. (English)

1 reference

19 April 2018

1 reference

D Wilkinson

1

1 reference

19 April 2018

C Stave

series ordinal

2

1 reference

19 April 2018

D Keohane

series ordinal

3

1 reference

19 April 2018

O Vincenzino

series ordinal

4

1 reference

19 April 2018

publication date

1 March 2004

1 reference

19 April 2018

Journal of International Medical Research

published in

1 reference

19 April 2018

volume

32

1 reference

19 April 2018

issue

2

1 reference

19 April 2018

page(s)

149-159

1 reference

19 April 2018

Studies on the incidence of dementia: the European perspective

cites work

1 reference

https://api.crossref.org/works/10.1177%2F147323000403200207

The burden of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000403200207

The cholinergic hypothesis of Alzheimer's disease: a review of progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000403200207

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000403200207

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000403200207

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000403200207

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000403200207

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000403200207

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000403200207

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000403200207

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000403200207

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000403200207

Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000403200207

Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000403200207

A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000403200207

An observational clinical study of the efficacy and tolerability of donepezil in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000403200207

Alzheimer's disease care: costs and potential savings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000403200207

An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000403200207

Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000403200207

10.1177/147323000403200207

21 January 2018

Identifiers

DOI

1 reference

19 April 2018

1 reference

19 April 2018